Metsera announced that it has amended the merger agreement with Pfizer pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, according to a statement.
- Consists of $65.60 per share in cash and a contingent value right entitling holders to additional payments of up to $20.65 per share in cash
- Metsera’s Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer
- Parties expect to close promptly following the stockholder meeting on Nov. 13
To view the source of this information, click
To contact ...